Amundi Innoviva, Inc. Transaction History

Amundi

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$14.56 - $16.78 $24,752 - $28,526	1,700 Added 22.65%	9,207 $140,000
Q3 2023 Nov 14, 2023	SELL	$12.37 - $13.89 $7,483 - $8,403	-605 Reduced 7.46%	7,507 $97,000
Q2 2023 Aug 14, 2023	SELL	$11.39 - $13.72 $20,889 - $25,162	-1,834 Reduced 18.44%	8,112 $103,000
Q1 2023 May 15, 2023	BUY	$10.73 - $13.6 $91,709 - $116,239	8,547 Added 610.94%	9,946 $111,000
Q4 2022 Feb 14, 2023	BUY	$11.8 - $13.78 $16,508 - $19,278	1,399 New	1,399 $18,000
Q2 2022 Aug 15, 2022	BUY	$14.32 - $19.88 $20,033 - $27,812	1,399 New	1,399 $20,000
Q3 2021 Nov 15, 2021	SELL	$13.06 - $17.24 $182,134 - $240,429	-13,946 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$11.45 - $13.96 $159,681 - $194,686	13,946 New	13,946 $187,000

228

79.1M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.33B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

Stay updated on Amundi with notifications on news.